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Abstract
Background: Cell-surface glycoproteins play critical roles in cell-to-cell recognition, signal transduction and regulation, 
thus being crucial in cell proliferation and cancer etiogenesis and development. DPP IV and NEP are ubiquitous 
glycopeptidases closely linked to tumor pathogenesis and development, and they are used as markers in some 
cancers. In the present study, the activity and protein and mRNA expression of these glycoproteins were analysed in a 
subset of clear-cell (CCRCC) and chromophobe (ChRCC) renal cell carcinomas, and in renal oncocytomas (RO).
Methods: Peptidase activities were measured by conventional enzymatic assays with fluorogen-derived substrates. 
Gene expression was quantitatively determined by qRT-PCR and membrane-bound protein expression and 
distribution analysis was performed by specific immunostaining.
Results: The activity of both glycoproteins was sharply decreased in the three histological types of renal tumors. 
Protein and mRNA expression was strongly downregulated in tumors from distal nephron (ChRCC and RO). Moreover, 
soluble DPP IV activity positively correlated with the aggressiveness of CCRCCs (higher activities in high grade tumors).
Conclusions: These results support the pivotal role for DPP IV and NEP in the malignant transformation pathways and 
point to these peptidases as potential diagnostic markers.
Background
Although never demonstrated in human, a wide variety of
factors have been reported to be involved in renal cancer
development in experimental animals [1]. Clinical data
support that Renal Cell Carcinomas (RCCs) are neo-
plasms with high prevalence and mortality rates [2]. His-
tologically, they represent a heterogeneous group of
tumors with different behavior and prognosis ranging
from benign tumors to extremely aggressive cancers who
have been reclassified in the last WHO classification of
renal tumors [3]. However, the underlying phenomena
related with the wide prognostic spectrum of this group
of tumors are a permanent matter of debate far to be
understood. To date, there is no clinical marker to detect
the disease in the asymptomatic potentially curable phase
nor to predict with reliability the clinical course of every
case. Only classical parameters like histological type,
stage and grade may help for such a purpose, but depend-
ing on the clinical setting and other patient's circum-
stances, many individual cases often escape the general
rules of tumor behavior making necessary the discovering
of more predictable parameters.
The increased knowledge of these tumors has led to the
implication of several proteinases in its genesis, growth
and dissemination, and most efforts have been directed
towards the understanding of the role of matrix metallo-
proteinases [4,5]. However, very little is known about the
implication of other proteinases such as peptidases.
Several peptidases are well-known membrane-bound
glycoproteins which present a demonstrated potential as
prognostic and diagnostic markers in solid tumors.
Among them, two glycopeptidases have been broadly
related to exert pivotal roles in cancer pathophysiology;
dipeptidyl peptidase IV (DPP IV), identical with CD26 or
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gp110-EC 3.4.14.5-, and neutral endopeptidase (NEP),
also CD10 or CALLA glycoprotein-EC 3.4.24.11 - [6-8].
Normally, DPP IV and NEP act as regulatory proteins
in cancer progression and development by modulating
the effects of biologically active peptides, but eventually,
they also can act as proteinases which execute extracellu-
lar matrix degradation [6,7].
DPP IV is a 110-kDa ectoenzyme that belongs to the
serine protease family. It is widely expressed in endothe-
lial and epithelial cells, several critical chemokines and
cytokines being its natural substrates [9].
NEP is a 90-110 kDa membrane-bound glycoprotein
which is normally expressed in most mammalian tissues
and belongs to the M13 family of zinc peptidases. Natural
substrates for NEP are enkephalins, angiotensins, brady-
kinin, tachykinins, oxytocin, endothelin-1, bombesin and
bombesin-like peptides [7,10].
Aside from its ability to regulate the effect of biological
factors through its enzymatic activity, several data sug-
gest that both glycoproteins exert other functions which
contribute to tumor etiopathogenesis. Thus, NEP can
influence by itself some signal transduction pathways that
regulate cell-growth, migration, and apoptosis [7], and
DPP IV may work as a functional collagen receptor with
roles in T-cell activation in thymic ontogeny [6] and also
regulate tumor cell behavior through interaction with
fibroblast activation protein-α[11].
DPP IV and NEP biological actions are being increas-
ingly elucidated in the last years and their role in renal
tumor genesis and development is an emerging issue with
potential clinical implications
Some of our previous studies in this field have demon-
strated that membrane-bound peptidases, including two
glycoproteins (APA/gp160 and APN/gp150), could be
involved in renal cancer etiogenesis. In particular, we
have described a striking reduction in the activity of APA,
APN and APB peptidases, which could be related to the
histogenetic origin of the most frequent renal tumor sub-
types [12,13].
In this manuscript, we present the metabolic and
expression profiling of DPP IV and NEP glycoproteins in
three main histological types of renal tumors (covering
80% of these neoplasms), namely CCRCC, ChRCC and
RO. Additionally, this profiling is also presented in differ-
ent CCRCC grades and stages, two key histopathological
parameters for tumor prognosis [3].
Methods
The authors declare that all the experiments carried out
in this study comply with current Spanish and European
Union laws and conform to the principles outlined in the
Declaration of Helsinki.
Renal tissue specimens and sample storage
We analyzed renal tissue in a series from 75 patients with
CCRCC (60 male, 15 female; mean age: 63 years), 10
patients with ChRCC (4 male, 6 female; mean age: 65
years) and 8 patients with RO (6 male, 2 female; mean
age: 68 years). Patient consent and Hospital Ethics Com-
mittee approval were obtained a priori. Fresh tissue sam-
ples were obtained from surgical specimens from renal
tumor patients. Tumor and normal (surrounding unin-
volved tissue) areas were obtained in all cases. For RT-
PCR studies, tissue samples were immersed in RNAlater
(Ambion, Huntingdon, UK) immediately after dissection
and stored at -80°C until use. For activity studies, tissue
samples were embedded in OCT, frozen in isopentane,
and stored a t -80°C until the enzyme assa ys were per -
formed. In addition, selected tissue samples were forma-
lin-fixed and paraffin-embedded for
immunohistochemistry assay of DPP IV and NEP and for
histopathological diagnosis. The 2004 WHO histological
classification of adult renal cell tumors [3], the 2002 TNM
Edition for tumor staging [14], and the Furhman's
method for grading [15] were used for performing the
histopathological diagnoses.
Quantitation of DPP IV and NEP Catalytic Activity
Sample preparation
Explanted tissue samples were homogenized in 10 mM
Tris-HCl buffer, pH 7.4, for 30 seconds at 800 rpm using a
Heidolph PZR 50 Selecta homogenizer and ultracentri-
fuged in a Centrikon T-2070 Kontron Instruments appa-
ratus at 100,000 g for 35 min. The resulting supernatants
were used to measure soluble DPP IV activity, which is a
truncated form of membrane-bound DPP IV/CD26 lack-
ing some residues in the N-terminal aminoacids [16]. To
avoid contamination with soluble enzymes, the resulting
pellets were washed three times by suspension in 10 mM
Tris-HCl buffer, pH 7.4. The pellets were then homoge-
nized in 10 mM Tris-HCl buffer, pH 7.4, and centrifuged
at low speed (1,500 g) for 1 min to purify the nucleus
from the samples. The supernatants thus obtained were
used to determine particulate enzyme activities and pro-
tein concentrations. All steps were carried out at 4°C.
Enzyme assays
A l l  r e a g e n t s  u s e d  i n  t h e s e  a s s a y s  w e r e  p u r c h a s e d  b y
Sigma-Aldrich®, Spain division.
DPP IV activity was measured in triplicate by using H-
Gly-Pro-β-naphthylamide as substrate, following the
method of Liu and Hansen [17]. The NEP assay was car-
ried out by incubating samples with a saturating concen-
tration of N-Dansyl-D-Ala-Gly-pNOH2-Phe-Gly ([D]AG
(pN)PG, a Dansyl derivative), following the method of
Florentin et al. (1984) [18].Varona et al. BMC Cancer 2010, 10:193
http://www.biomedcentral.com/1471-2407/10/193
Page 3 of 11
These assays are based on the fluorescence of products
generated from the hydrolysis of the substrate by the
enzyme. Reactions were initiated by adding 30-50 μL of
sample to 1 mL of the appropriate incubation mixture (50
mM Tris-HCl buffer, pH 7.4, and 0.2 mM aminoacyl-β-
naphthylamide or 0.125 mM [D]AG(pN)PG). After 30
min incubation at 37°C, 1 mL of 0.1 M sodium acetate
buffer (pH 4.2) was added to the mixture to terminate the
reaction. The released product was determined by mea-
suring the fluorescent intensity (at 412 nm with excita-
tion at 345 nm for β-naphthylamine, and at 562 nm with
excitation at 342 nm for [D]AG) with a Shimadzu RF-540
Spectrofluorophotometer. Blanks were used to determine
background fluorescence. The relative fluorescence was
converted into picomoles of product using a standard
curve constructed with increasing concentrations of β-
naphthylamine or [D]AG.
Protein determination
Protein concentration was measured in triplicate by the
method of Bradford, using BSA (1 mg/mL) as the calibra-
tor. The results were recorded as units of peptidase (UP)
per milligram of protein. One unit of peptidase activity is
the amount of enzyme necessary to release one pmol of
fluorogenic product per minute (pmol/min). Fluorogenic
assays were linear with respect to hydrolysis time and
protein content.
Quantitation of DPP IV and NEP mRNA expression
RNA isolation
Quantitative RT-PCR for detecting DPP IV and NEP
mRNA (DPP4  and  MME  genes respectively) was per-
formed to assess the transcription levels of these pepti-
dases. To avoid any RNA degradation only samples that
were immediately immersed in RNAlater after dissection
w e r e  u s e d  i n  t h e s e  e x p e r i m e n t s .  H e n c e ,  t o t a l  R N A  o f
tumor and non-tumor tissue samples from 26 CCRCC
(21 male, 5 female; mean age: 63 years), 6 ChRCC (2 male,
4 female; mean age: 63 years) and 4 RO (4 male, 0 female;
mean age: 63 years) patients was isolated following a
standard protocol as previously described [19]. Briefly,
after homogenization of the samples, total RNA was iso-
lated with TRIzol Reagent (Invitrogen Life Technologies,
Karlsruhe, Germany) according to the manufacturers
manual, using approximately 50 mg frozen tissue per mil-
liliter TRIzol.
Real-time quantitative RT-PCR Analysis
First-strand cDNA was synthesized from 25 μg of total
RNA of each human sample using Moloney murine leu-
kemia virus reverse transcriptase and random hexamers
according to the manufacturer's instructions (First-strand
cDNA Synthesis Kit, Amersham Biosciences, Essex, UK).
The resulting cDNA samples were amplified by PCR with
specific oligonucleotide primer pairs designed with the
analysis software Primer 3 [20]. Based on previous exper-
iments on human renal cell carcinoma [19,21] and other
human tissues [22,23] we chose TATA box binding pro-
tein (TBP), peptidylprolyl isomerase A (PPIA), β-actin
(ACTB) and succinate dehydrogenase complex, subunit A
(SDHA) as endogenous reference genes. The sequence of
the primers used to amplify DPP4, MME and the four
housekeeping genes are shown in Table 1. All primers
were synthesized and purified by Sigma-Genosys (Cam-
bridge, UK).
The expression of the housekeeping genes, DPP4 and
MME  was quantified in all cDNAs by real-time PCR
using the iCycler iQ real-time detection apparatus (Bio-
Rad Laboratories, Hercules, CA, USA). Dilutions of the
cDNA template were prepared from each tissue and
amplified in triplicate using SensiMix Plus SYBR + FLU-
ORESCEIN (Quantace Ltd., London, UK). Three negative
controls (with no template, no reverse transcriptase and
no RNA in the reverse transcriptase reaction) were also
Table 1: Sequence of forward (F) and reverse primers (R) of indicated target genes and the size expected for each PCR-
amplified product.
Peptidase Gene symbol Fordward primer Reverse primer Amplicon size (bp)
DPPIV/gp110 DPP4 5'-AGTGGCGTGTTCAAGTGTGG-3' 5'-CAAGGTTGTCTTCTGGAGTTGG-3' 112
NEP/CALLA glycoprotein MME 5'-CCGAGAAAAGGTGGACAAAGA-3' 5'-GGACTGCTGGGCACTAAAGAA-3' 133
Housekeeping Gene name
β-actin ACTE 5'-TCCCTGGAGAAGAGCTACGA-3' 5'-ATCTGCTGGAAGGTGGACAG-3' 362
Succinate dehydrogenase 
complex, subunit A
SDHA 5'-TCTGCCCACACCAGCACT-3' 5'-CCTCTCCACGACATCCTTCC-3' 142
TATA box binding protein TBP 5'-GGATAAGAGAGCCACGAACCAC-3' 5'-TTAGCTGGAAAACCCAACTTCTG-3' 139
Peptidylpropyl isomerise A PPIA 5'-GGTCCCAAAGACAGCAGAAAA-3' 5'-TCACCACCCTGACACATAAACC-3' 114
Primers for the assayed housekeeping genes are also shown.Varona et al. BMC Cancer 2010, 10:193
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included in each plate to detect any possible contamina-
tion. After a hot start (10 min at 94°C), the parameters
used for PCR amplification were: 10 s at 94°C, 20 s at
60°C and 30 s at 72°C, for 50 cycles.
Real-time PCR data were expressed as the fold change
of the target gene expression relative to the geometric
mean (g.m.) mRNA expression of the housekeeping genes
in each sample, as described by Vandesompele et al. [24].
The fold change in gene expression was calculated by the
formula: 2-ΔC
T, where CT is the threshold cycle, calculated
by the iCycler software, ΔCT = (CTtarget gene - CTg.m. reference
genes) and ΔΔCT = (ΔCTtest sample - ΔCTcontrol sample).
For each type of renal tumor, paired malignant (tumor)
and uninvolved surrounding samples (normal) from the
same patient were always measured in the same analytical
run to exclude between-run variations. PCR data
obtained in one of the normal kidney samples were arbi-
trarily chosen as control, and this sample was included in
all PCR experiments to correct for possible interassay
variations. As was for the enzymatic activities, an addi-
tional assay-set was performed to compare expression
levels of MME and DPP4 between different grades and
stages in CCRCC samples.
As indicated in previous works, specifically in the field
of RCCs, expressions measured in these systems may not
always be normally distributed. Thus, we performed a
D'Agostino & Pearson omnibus normality test. Since
expression data for the three tumor types fitted to a
Gaussian distribution, the unpaired t test was applied for
all significance calculations.
Semiquantitative evaluation of DPP IV and NEP expression 
in renal tumors
Immunohistochemistry
Conventional tissue samples from patients with different
tumor-phenotypes (CCRCC; ChRCC; RO) and their nor-
mal tissues were subjected to immunohistochemistry
using a rabbit polyclonal antibody specific for DPP IV/
CD26 (Abcam plc, Cambridge, UK) at 1:250 working
dilution, and a rabbit monoclonal antibody specific for
NEP/CD10 (Novocastra, Newcastle, UK) at 1:30 working
dilution.
Briefly, endogenous peroxidase activity was blocked by
incubating the slides in 3% hydrogen peroxide in absolute
methanol for 10 minutes. Antigen retrieval was carried
out in citrate buffer (10 mM, pH = 6) for 15 minutes at
100°C in a microwave oven. The primary antibody was
applied for 1 hour at room temperature. A subsequent
reaction was performed with secondary antobodies and
biotin-free HRP enzyme labeled polymer of the EnVision-
plus detection system (Dako, Carpinteria, CA). Nonspe-
cific IgG was used as a negative control. A positive reac-
tion was visualized with diaminobenzydine solution
followed by counterstaining with hematoxylin.
Clinical evaluation
All the sections were evaluated microscopically by using
conventional techniques in the Laboratory of Anatomic
Pathology. A section was considered negative or positive
according to the absence or presence of staining. Two
independent observers blinded from the clinical data
analyzed separately the immunostaining reactions for
both peptidases. Positive immunoreactivity was assessed
by the relative intensity of staining in the sample. Thus
the immunostaining results were divided into 4 catego-
ries: negative (-; lack of specific staining); mild staining
(+); moderate staining (++); intense staining (+++).
Respectively, each positive staining was subdivided into 2
categories: diffuse staining; focal staining.
Statistical analyses
Data were analyzed statistically using SPSS©. Unpaired
Student's t test was performed to detect differences
between uninvolved tissues and tumors, as well as among
low and high grades and stages. Statistically significant
differences were considered at p < 0.05.
Results
DPP IV and NEP activity profile in renal tumors
Data obtained in the activity assays of both glycoproteins
across the different tumor types and in stratified CCRCC
are given in Figures 1 and 2.
Figure 1 shows DPP IV and NEP activities measured in
tumor and non-tumor tissue (normal) of CCRCC (n =
75), ChRCC (n = 10) and RO (n = 8) patients. Activity is
recorded as pmol of product/min/mg protein (UP/mg
protein) and presented as mean ± SE.
As shown in Figure 1A, when compared with non-
tumor tissues, soluble DPP IV activity decreased signifi-
cantly (fivefold) only in chromophobe carcinomas. Values
for the soluble DPP IV activities in CCRCC and in RO did
not vary significantly.
The membrane-bound DPP IV activity in renal tumors
(Figure 1B) decreased significantly in all tumor types we
analyzed (CCRCC, ChRCC and RO) when compared
with the normal tissue samples. Loss of activity was slight
in CCRCC (twofold), whereas it drastically decreased in
the ChRCC (sixteenfold) and, although in a lesser inten-
sity, in the RO (sixfold).
With respect the NEP activity, it is shown in Figure 1C.
As in the case of the aforementioned membrane-bound
glycoprotein, NEP activity decreased significantly in
CCRCC (fourfold), ChRCC (fivefold) and RO (sevenfold)
when compared with the normal tissue samples. We did
not detect any NEP activity in the soluble fraction (data
not shown).
Figure 2 represents DPP IV and NEP activity in the dif-
ferent stages and grades of CCRCC group (Low grade:
G1-G2, n = 38 vs High grade: G3-G4., n = 37; Low stage:
T1-T2, n = 48 vs High stage: T3-T4, n = 27). Activity isVarona et al. BMC Cancer 2010, 10:193
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recorded as pmol of product/min/mg protein (UP/mg
protein) and presented as mean ± SE.
The study of DPP IV yielded significant results (Figure
2A). After stratification by grade, soluble (s)DPP IV activ-
ity was twofold significantly decreased in CCRCCs with a
low Furhman's grade in comparison to those clear cell
carcinomas in a higher grade. Statistical analyses of grad-
ing for cell surface DPP IV (DPP IV/CD26) and staging
for both soluble and membrane-bound DPP IV activities
were not significant.
In Figure 2B, NEP activities in graded and staged
CCRCCs are shown. No significant changes were found
after stratification of this activity.
Figure 1 Soluble (A) and membrane-bound DPP IV (B), and NEP (C) peptidase activity profiles in clear cell renal cell carcinoma (CCRCC), 
chromophobe renal cell carcinoma (ChRCC) and renal oncocytoma (RO). Columns compare tumor with non-tumor surrounding tissue (normal). 
Values represent mean ± SE of units of peptidase (UP) per milligram of protein.
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Quantitative DPP IV and NEP expression profile in renal 
tumors
Data obtained in the qRT-PCR assays of both glycopro-
teins across the different tumor types and in stratified
CCRCC are given in Figures 3 and 4.
Figure 3 shows the DPP IV and NEP mRNA levels mea-
sured in tumour and nontumour tissue (normal) for
CCRCC (n = 26), ChRCC (n = 6) and RO (n = 4) patients.
RT-PCR data for each analyzed sample are recorded as
r e l a t i v e  u n i ts,  a s  c a l c u l a t e d  b y  t h e  Δ Δ C T method. The
mean ± SE, p values and "normal/tumour" ratio of expres-
sion levels are also represented.
Significant decreases of expression levels were only
observed in the ChRCC when compared with the normal
tissue. Thus, DPP IV relative expression (Figure 3A)
decreased fortysixfold in chromophobe RCCs, whereas
NEP mRNA levels (Figure 3B) decreased sixtysevenfold
in the same tumor-type.
Changes were not significant for DPP IV (Figure 3A)
nor NEP expression (Figure 3B) in CCRCC and RO
tumors when compared with their corresponding normal
tissues. However, such as in activity assays, a decreasing
trend of mRNA levels was also observed for DPP IV in
RO and for NEP in CCRCC and RO. Thus, as shown in
Figure 3A, DPP IV expression did not change in CCRCC,
and it decreased twofold in RO. NEP expression levels
(Figure 3B) decreased twofold in CCRCC and thirtyfold
in RO.
Figure 4 shows the DPP IV and NEP mRNA levels mea-
sured in the different grades and stages of CCRCC group
(Low grade: G1-G2, n = 12 vs High grade: G3-G4, n = 14;
Low stage: T1-T2, n = 16 vs High stage: T3-T4, n = 10).
RT-PCR data for each analyzed sample are recorded as
relative units, as calculated by the ΔΔCT method. The
mean ± SE, p values and "normal/tumour" ratio of expres-
sion levels are also represented.
We did not find significant variations of expression in
CCRCC related to its stratification in grades and stages,
either in DPP IV (Figure 4A) nor in NEP mRNA levels
(Figure 4B).
Membrane-bound protein expression (Semiquantitative 
Immunostaining)
DPPIV and NEP immunostaining distribution in renal
tumours and normal kidney is presented in Table 2 and in
Figures 5, 6 and 7. Semiquantitative features recorded in
this table were the relative intensity of specific staining
for both DPP IV and NEP glycoproteins (negative, mild,
moderate, intense), and the distribution of that staining
(diffuse, focal), in tumor types.
DPP IV specific staining was moderate and diffuse in
the CCRCC (Figure 5B), however there was not immuno-
reaction to this cell-surface protein in the ChRCC (Figure
5E) nor in the RO (Figure 5H).
In contrast, immunostaining for NEP was positive in all
the tumor-types we analyzed. Thus, NEP staining was
intense and diffuse in the CCRCC (Figure. 5C), whereas it
was mild and focal in both ChRCC (Figure 5F) and RO
(Figure 5I).
A positive immunostaining with DPPIV/CD26 (Figure
6) and NEP/CD10 (Figure 7) was found in the proximal
tubules of normal kidney. Conversely, distal tubules were
negative.
Discussion
In this manuscript we assessed DPP IV and NEP catalytic
activitiy, membrane-bound expression, and mRNA levels
Figure 2 Soluble (s) and membrane-bound DPP IV (A), and NEP (B) peptidase activity profiles in different grades and stages of clear cell 
renal cell carcinoma (CCRCC). Columns compare high grade (G3-G4) and stage (T3-T4) tumors with low grade (G1-G2) and stage (T1-T2) tumors. 
Values represent mean ± SE of units of peptidase (UP) per milligram of protein.
 
A                           B  
 
 
U
P
/
m
g
 
p
r
o
t
e
i
n
 
0
2000
4000
6000
8000
10000
12000
14000
(s)DPPIV DPPIV/CD26 (s)DPPIV DPPIV/CD26
Low grade/stage
High grade/stage
Furhman's grade TNM stage
p<0.05
2-fold

0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
NEP NEP
Furhman's grade TNM stageVarona et al. BMC Cancer 2010, 10:193
http://www.biomedcentral.com/1471-2407/10/193
Page 7 of 11
in a subset of renal tumors and found that both glycopro-
teins were selectively altered in neoplastic tissue. Enzyme
activities were significantly decreased in the tumor tissue
of all histological types, a trend which was especially
sharp in ChRCC and RO. With respect to protein expres-
sion, DPP IV and NEP were down-regulated in ChRCC
and RO, whereas CCRCC showed a moderate to strong
immunostaining. This pattern was similar to that
observed at mRNA levels. Thus, the relative expression of
DPP4 (DPP IV transcriptome) and MME (NEP transcrip-
tome) genes were found to be strongly decreased in
ChRCC samples (DPP IV: ￿ fortysixfold, NEP: ￿ sixtysev-
enfold; tumor vs normal) and, although no statistically
significant, slightly to strongly down-regulated in RO
(DPP IV: ￿ twofold, NEP: ￿ thirtyfold; tumor vs normal).
In contrast, mRNA levels for both glycoproteins did not
significantly vary in CCRCC when compared with its
normal tissue.
A main result in this work is that both glycoproteins
showed a distinct pattern when compared tumors with
the normal sorrounding tissues. DPP IV and NEP activi-
ties were markedly decreased in all tumor subtypes, and
protein and mRNAs were strongly down-regulated in
ChRCC and RO. These results agree with previous stud-
ies indicating that modifications in the activity and
expression profiles of DPP IV and NEP are key events in
malignant tumors, pointing to an involvement of these
proteins in tumor cell growth, local invasion and metas-
tasis [7,25-27]; and, in addition, this study extend that
role of both peptidases to the renal tumors. Moreover, the
present manuscript shows that the modifications affect-
ing DPP IV and NEP profiles along the different pheno-
types of renal cancer are similar to those we observed in
our previous studies on other membrane-bound pepti-
dases, such as IRAP, APN and APA [12,13,28], and thus
reinforces the idea that loss of several physiologically sig-
nificant glycopeptidases may be a critical step in the etio-
genesis of renal tumors. To support this fact, it has been
described that membrane-bound ectopeptidases can
affect, in solid tumors, cellular events classically shown to
be influenced by matrix metalloproteinases (MMPs) and
other secreted proteases [27].
Figure 3 mRNA levels of DPP IV (A) and NEP (B) measured in tumour and nontumour tissue (normal) for CCRCC (n = 16), ChRCC (n = 6) and 
RO (n = 4) patients. RT-PCR data for each analyzed sample are recorded as relative units. The mean ± SE, p values and "normal/tumour" ratio of ex-
pression levels are also represented. *Statistically significant. ns no significant.
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This study also demonstrates a different DPP IV and
NEP protein and mRNA expression depending on tumor
type. Immunostaining in normal renal tissue revealed
that both enzymes were exclusively located in the proxi-
mal nephron, the proposed site of origin of CCRCC [3],
which showed moderate to intense positivity. Conversely,
protein expression and mRNA levels of tumors suppos-
edly derived from the distal nephron (ChRCC and RO)
were markedly down-regulated. This work agrees with
previous studies [29-34] and further supports the theory
of the different origin of tumors along the nephron pro-
posed in the 2004 WHO classification [3].
The exact role that DPP IV plays in different cancers
remains unclear, partially due to its variable expression
along the different tumor-types. Thus, both up- and
down-regulation of this protein have been described
depending on the studied tumor and organ [6,26]. With
respect to the relationship between DPP IV expression
and cancer, the unique example of a clear causal effect is
seen in human melanocytes where the loss of DPP IV is
invariably associated with malignant transformation [35].
We also have observed a down-regulation in the activity
and expression of this glycoprotein in renal tumors, and
in this sense our results agree with those described in the
human melanoma [36].
DPP IV is a glycoprotein which presents demonstrated
pleiotropic effects, and it is likely that this multifunction
accounts for its varied roles in different cancers. Thus,
there may be two main mechanisms by which DPP IV
affects cellular function: on one hand its catalytic activity
on bioactive peptides and, on the other hand, its direct
interaction with certain molecules located outside the
cells [9,26,36]. This feature makes difficult to ascertain
which is the exact way DPP IV plays in cancer, and fur-
Figure 4 mRNA levels of DPP IV (A) and NEP (B) measured in different grades and stages of clear cell renal cell carcinoma (CCRCC). RT-PCR 
data for each analyzed sample are recorded as relative units. The mean ± SE, p values and "normal/tumour" ratio of expression levels are also repre-
sented. *Statistically significant. ns no significant.
Fig. 4a DPP IV expression in stratified CCRCCs
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Fig. 4b NEP expression in stratified CCRCCs
Low Grade High Grade Low Stage High Stage
0
1
2
3
4
5
6
M
M
E
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
(
r
e
l
a
t
i
v
e
 
u
n
i
t
s
)
Furhman’s Grade  Furhman’s Grade TNM  Stage  TNM Stage 
ns p = 0.1726 
 2.5-fold 
ns p = 0.2495 
 1.5-fold 
ns p = 0.1931 
 1.5-fold 
ns p = 0.1754 
 1.5-fold 
A  B 
Table 2: Semiquantitative evaluation of renal tumors. (-) Negative immunostaining; (+) Mild immunostaining; (++) 
Moderate immunostaining; (+++) Intense immunostaining.
DPP IV/CD26 immunostaining NEP/CD10 immunostaining
Tumor tissue Staining-intensity Staining-intensity
CCRCC ++ diffuse +++ diffuse
ChRCC -+  f o c a l
RO -+  f o c a l
Normal tissue + +++Varona et al. BMC Cancer 2010, 10:193
http://www.biomedcentral.com/1471-2407/10/193
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Figure 5 Immunohistochemistry of DPP IV and NEP in renal tumors. Hematoxylin and eosin staining of CCRCC (A), ChRCC (D) and RO (G). DPP IV/
CD26 staining of CCRCC (B), ChRCC (E) and RO (H). NEP staining of CCRCC (C), ChRCC (F) and RO (I). Tissues magnification at 400×.
Figure 6 Immunohistochemistry of DPP IV and NEP in normal re-
nal tissue. DPP IV immunostainings are selectively located in proximal 
tubules. Tissues magnification at 400×
Figure 7 Immunohistochemistry of DPP IV and NEP in normal re-
nal tissue. NEP immunostainings are selectively located in proximal 
tubules. Tissues magnification at 400×Varona et al. BMC Cancer 2010, 10:193
http://www.biomedcentral.com/1471-2407/10/193
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ther investigations are required to elucidate the concrete
molecular mechanisms of this glycopeptidase in renal
tumor biology.
DPP IV has been commonly described as a membrane-
bound peptidase, but the expression and activity of solu-
ble isoforms ha ve been reported in body fluids and in
cytosolic fractions [6,37,38]. Previous studies have
reported altered soluble DPP IV activities in several neo-
plasms, suggesting the potential value of this enzyme as a
prognostic variable of cancer patients [6,39]. In this sense,
we have found that soluble DPP IV activity significantly
decreased (twofold) in low grade CCRCCs (G1-G2) when
compared with their more aggressive counterparts (high
grade: G3-G4). In addition, although no statistically sig-
nificant, we also observed a decreasing trend between
activities of different CCRCC stages in both soluble
(22%￿; low vs high stage) and membrane-bound DPP IV
(19%￿; low vs high stage). A similar phenomenon has
been observed previously with other peptidases and kal-
likreins in renal carcinomas [13,36,40], suggesting that
these proteases may predict a poor disease outcome in
RCC.
Several authors have referred to the potentiality of
NEP/CD10 as diagnostic marker in the RCCs [29,30].
Thus, NEP (CD10) is a useful immunohistochemical
marker in the identification of proximal nephron-derived
carcinomas such as CCRCC [31], and usually shows neg-
ative immunostaining in distal nephron-derived tumors
like ChRCC [32]. However, although the immunohis-
tochemical expression patterns of NEP along the renal
cancer have been broadly documented, works on activity
and mRNA profiles of this glycoprotein in renal tumors
are lacking. In this sense, our results add new findings to
understand the role of NEP in RCCs.
Loss or decrease in NEP expression has been reported
in several cancer types, such as invasive bladder carci-
noma, poorly differentiated gastric adenocarcinoma,
small cell and non-small cell lung carcinomas, endome-
trial adenocarcinoma and prostate adenocarcinoma
[41,42]. Our data on NEP activity, immunostaining and
mRNA agree with general findings about these enzymes
in the human neoplasia, extending this knowledge to
renal tumors as previously reported [43].
NEP has also been demonstrated to be a multifunc-
tional glycoprotein. It is accepted that the interactions of
this membrane-bound peptidase with other transmem-
brane proteins and/or the extracellular matrix (ECM)
may have similar or even more relevance in regulating
cells than cleaving bioactive peptides [7]. NEP is consid-
ered to be a tumor suppressor protein which, in addition,
interacts with other tumor suppressors such as PTEN
[7,44], demonstrating an anti-angiogenic effect [42].
Since, as we observed, a strong decrease in NEP activity
and expression appears to be a common feature in the
renal tumor etiogenesis, our data may support a potential
anti-tumor function of NEP in renal cancer.
Conclusion
This work demonstrates a strong downregulation of DPP
IV and NEP in the renal tumors, different protein and
mRNA expression profiles, which depend on the tumor
type, and a positive correlation between soluble DPP IV
activity and aggressiveness in CCRCCs. These results
support the idea of a pivotal role for DPP IV and NEP in
the malignant transformation of renal neoplasms and
stress the importance of both glycoproteins as potential
diagnostic tools. Further studies comparing enzymatic
activities and expression profiles with patient survival will
help us to determine the approppriate use of DPP IV and
NEP also as prognostic tools.
Nonstandard Abbreviations
CALLA: (common acute lymphoblastic leukemia anti-
gen); CCRCC: (clear-cell renal cell carcinoma); ChRCC:
(chromophobe renal cell carcinoma); DPPIV: (dipeptidyl
peptidase IV); NEP: (neprilysine, neutral endopeptidase);
RO: (renal oncocytoma); UP: (Units of Peptidase, pmol of
product/min).
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